Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.75 Average PT from Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.75.

A number of analysts have recently issued reports on the stock. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Mizuho dropped their price objective on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Finally, Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 14th.

Autolus Therapeutics Trading Up 3.0%

NASDAQ:AUTL opened at $1.70 on Monday. The business’s fifty day moving average price is $1.50 and its 200 day moving average price is $1.52. The firm has a market capitalization of $452.44 million, a price-to-earnings ratio of -1.56 and a beta of 1.93. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The firm had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Equities analysts forecast that Autolus Therapeutics will post -0.97 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently bought and sold shares of AUTL. Independent Advisor Alliance acquired a new position in Autolus Therapeutics in the 4th quarter worth about $28,000. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $28,000. Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $37,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Autolus Therapeutics in the third quarter worth approximately $46,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.